SCHEMBL24309831

SCHEMBL24309831

Cn1cc(S(=O)(=O)Nc2nc(Cl)c(F)c(Cl)n2)cn1

nearest known ligand 0.42

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ KAT6A Q92794 1/20 0.41
▸ KAT5 Q92993 1/20 0.41
▸ BRD4 O60885 1/20 0.38
▸ NLRP3 Q96P20 1/20 0.37
▸ BRAF P15056 1/20 0.36
▸ EGFR P00533 2/20 0.35
▸ FGFR1 P11362 2/20 0.35
▸ KDR P35968 2/20 0.35
▸ PTPN11 Q06124 1/20 0.35
▸ ALDH1A1 P00352 1/20 0.35
▸ HTT P42858 1/20 0.35
▸ SMN1; SMN2 Q16637 1/20 0.35
▸ L3MBTL1 Q9Y468 1/20 0.35
▸ MALT1 Q9UDY8 1/20 0.35
▸ CCNB2 O95067 4/20 0.35
▸ CDK1 P06493 4/20 0.35
▸ CCNB1 P14635 4/20 0.35
▸ CDK5 Q00535 4/20 0.35
▸ CDK5R1 Q15078 4/20 0.35
▸ CCNB3 Q8WWL7 4/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL24309813 0.89 NLRP3 (0.38) KAT6AKAT5NLRP3EGFRFGFR1
SCHEMBL24309366 0.87 PDE10A (0.38) KAT6AKAT5NLRP3EGFRFGFR1
SCHEMBL24310058 0.86 GAA (0.38) KAT6AKAT5NLRP3EGFRFGFR1
SCHEMBL26808422 0.85 KAT6A (0.39) KAT6AKAT5BRD4NLRP3EGFR
SCHEMBL24309413 0.85 KAT6A (0.35) KAT6AKAT5BRD4NLRP3EGFR
SCHEMBL24309501 0.85 MALT1 (0.37) KAT6AKAT5NLRP3EGFRFGFR1
SCHEMBL24309609 0.84 KAT6A (0.39) KAT6AKAT5BRD4NLRP3EGFR
SCHEMBL24309731 0.84 HTR1A (0.38) KAT6AKAT5NLRP3EGFRFGFR1
SCHEMBL24309573 0.84 HTR1A (0.38) KAT6AKAT5NLRP3EGFRFGFR1
SCHEMBL24309540 0.83 KAT6A (0.38) KAT6AKAT5BRD4NLRP3EGFR

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20230373935-A1 MODULATORS OF CYSTIC FIBROSIS TRANSMEMBRANE CONDUCTANCE REGULATOR VERTEX PHARMACEUTICALS, SAN DIEGO 2023-11-23 — — US disclosed
US-20230373935-A1 MODULATORS OF CYSTIC FIBROSIS TRANSMEMBRANE CONDUCTANCE REGULATOR VERTEX PHARMACEUTICALS, SAN DIEGO 2023-11-23 — — US disclosed
EP-4225748-A1 MODULATORS OF CYSTIC FIBROSIS TRANSMEMBRANE CONDUCTANCE REGULATOR Vertex Pharmaceuticals Incorporated (US) 2023-08-16 — — EP disclosed
WO-2022076627-A1 MODULATORS OF CYSTIC FIBROSIS TRANSMEMBRANE CONDUCTANCE REGULATOR VERTEX PHARMACEUTICALS INCORPORATED (US) 2022-04-14 — — WO disclosed
WO-2022076627-A1 MODULATORS OF CYSTIC FIBROSIS TRANSMEMBRANE CONDUCTANCE REGULATOR VERTEX PHARMACEUTICALS INCORPORATED (US) 2022-04-14 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230373935-A1 MODULATORS OF CYSTIC FIBROSIS TRANSMEMBRANE CONDUCTANCE REGULATOR CFTR, SCNN1G, SCNN1B KAT6A 2853/4885KAT5 3390/4885BRD4 1716/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback